10-Q: Modular Medical Faces Going Concern Doubt Amid Rising Losses

Modular Medical, a pre-revenue medical device company, reported increased operating losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Summary

• Modular Medical, a pre-revenue medical device company, reported a net loss of $14.5 million for the six months ended September 30, 2025, an increase from $9.1 million in the same period last year.
• Cash and cash equivalents decreased significantly to $5.3 million as of September 30, 2025, from $13.1 million at March 31, 2025.
• The company's accumulated deficit reached $99.2 million by September 30, 2025.
• Research and development (R&D) expenses surged by 55.3% to $10.7 million, and Selling, General and Administrative (SG&A) expenses increased by 69.2% to $3.9 million for the six months ended September 30, 2025, compared to the prior year.
• The company successfully completed a warrant inducement offering in September 2025, generating approximately $3.9 million in net proceeds, and raised an additional $0.7 million from at-the-market (ATM) stock sales during the six-month period.
• Subsequent to the reporting period, an additional $1.1 million was raised through ATM sales.
• Modular Medical received FDA clearance for its MODD1 pump in September 2024 and announced the first human use in August 2025.
• The 510(k) premarket notification for its next-generation Pivot pump was submitted to the FDA on November 13, 2025, with commercial launch expected in Q1 2026 upon regulatory approval.
• The company received a Nasdaq non-compliance letter on June 30, 2025, for failing to maintain a minimum bid price of $1 per share, with a deadline of December 29, 2025, to regain compliance.

Sentiment

Score: 3

Explanation: While there are positive developments in product regulatory progress and capital raising, the significant increase in net losses, substantial cash burn, explicit going concern warning, and Nasdaq delisting risk create a highly negative financial outlook. The company is pre-revenue and faces significant hurdles to achieve profitability and maintain liquidity.

Positives

• FDA clearance for the MODD1 pump was received in September 2024, and the first human use was announced in August 2025.
• The 510(k) premarket notification for the next-generation Pivot pump was submitted to the FDA on November 13, 2025, with commercial launch anticipated in Q1 2026.
• Successful capital raises through a warrant inducement offering ($3.9 million net proceeds) and at-the-market stock sales ($0.7 million during the period, plus $1.1 million subsequent to period end).
• Increased R&D and SG&A expenses reflect continued investment in product development and commercialization efforts, including a significant increase in R&D and SG&A employee headcount.

Negatives

• Net loss significantly increased to $14.5 million for the six months ended September 30, 2025, from $9.1 million in the prior year period.
• Cash and cash equivalents decreased by approximately 59.5% from $13.1 million at March 31, 2025, to $5.3 million at September 30, 2025.
• The company has an accumulated deficit of $99.2 million and does not currently generate revenue to cover operating expenses.
• Substantial doubt exists about the company's ability to continue as a going concern for at least one year from the financial statement issuance date.
• Received a Nasdaq non-compliance letter for failing to meet the minimum $1 bid price requirement, risking potential delisting.
• Operating cash burn increased to $10.8 million for the six months ended September 30, 2025, from $7.3 million in the prior year.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.
• Inability to raise sufficient additional capital through debt or equity arrangements on acceptable terms, leading to potential curtailment of product development, cost reductions, or termination of operations.
• Risk of delisting from Nasdaq due to failure to maintain the minimum $1 bid price requirement, which could adversely affect stock price, liquidity, and ability to raise future financing.
• Dependence on successful commercialization of pump products, competing technological and market developments, and the need for collaborations or acquisitions.
• Risks associated with the medical device industry, financing, liquidity requirements, rapidly changing customer requirements, limited operating history, and public market volatility.
• Inflationary risks, including increasing costs for components.

Future Outlook

Modular Medical expects to launch its next-generation Pivot pump commercially in the first quarter of 2026, pending FDA regulatory approval. The company anticipates continued increases in research and development and selling, general and administrative expenses as it expands its sales and marketing organization and invests in product commercialization. The ability to fund future operations and achieve profitability depends on generating significant revenue and successfully raising additional capital.

Management Comments

• "We are a pre-revenue medical device company focused on the design, development and commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace."
• "By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated super users and expand the category into the mass market."
• "We intend to initiate our commercial launch with the Pivot product, when the required regulatory approval from the FDA is received, which is expected in the first quarter of 2026."
• "Based on our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included in Item 1 of this Report are issued exists."
• "Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities, to support our future operations."

Industry Context

Modular Medical operates in the highly competitive and regulated medical device industry, specifically targeting the diabetes market with innovative insulin delivery systems. Its focus on simplifying the user experience and expanding beyond 'super users' to the mass market, including Type 2 diabetes patients, positions it against established players by aiming to disrupt the cost-complexity trade-off. The successful FDA clearance of MODD1 and the pending approval for Pivot are critical milestones in a market driven by technological advancements and patient convenience.

Comparison to Industry Standards

• Modular Medical is a pre-revenue company, making direct financial comparisons to established industry leaders like Medtronic, Insulet (Omnipod), or Tandem Diabetes Care challenging.
• Its strategy of developing a "two-part patch pump" and aiming for a simplified user experience targets a broader market, including Type 2 diabetes, which could differentiate it from competitors primarily focused on Type 1 diabetes or more complex systems.
• The company's significant R&D investment and increasing headcount are typical for a medical device company in the pre-commercialization phase, but the high cash burn and going concern warning highlight the substantial capital requirements and risks inherent in this stage compared to profitable industry peers.
• The pursuit of FDA 510(k) clearance for its Pivot product is a standard regulatory pathway for medical devices, aligning with industry practices for market entry.

Related Party Transactions

• Payments to a family member of an executive officer totaled approximately $86,460 for the six months ended September 30, 2025 (including stock options).
• Payments to a second family member of an executive officer (who consulted and became an employee in 2025) totaled approximately $34,600 for the six months ended September 30, 2025 (including stock options).

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing capital raises and potential loss of investment if the company cannot continue as a going concern. Also, risk of reduced liquidity and value due to potential Nasdaq delisting.
• Employees: Benefit from increased headcount in R&D and SG&A, but face uncertainty due to the going concern warning and potential cost-cutting measures if additional capital is not secured.
• Customers (future): Potential for innovative insulin delivery systems (MODD1, Pivot) to address unmet needs in the diabetes market, offering simplified user experience.
• Creditors: Face increased risk due to the company's substantial operating losses, negative cash flows, and going concern uncertainty.

Next Steps

• Obtain required regulatory approval from the FDA for the Pivot product, expected in Q1 2026.
• Initiate commercial launch of the Pivot product upon FDA approval.
• Obtain regulatory clearance to market and sell the Pivot product in foreign jurisdictions.
• Improve the manufacturability and usability of the Pivot product.
• Develop new pump products.
• Raise additional capital through equity or debt securities to support future operations.
• Regain compliance with Nasdaq's minimum bid price requirement by December 29, 2025, or seek an additional compliance period.
• Validate the manufacturing line for the Pivot pump product with capacity to serve 6,000 patients by March 15, 2026.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial increase in net losses, significant cash burn, and an explicit 'going concern' warning from both management and auditors. While product development (Pivot pump FDA submission) and capital raising efforts are ongoing, these are insufficient to offset the fundamental liquidity and profitability challenges. The Nasdaq non-compliance and delisting risk further compound the negative outlook, indicating a high probability of significant share price depreciation and reduced liquidity. Investors face substantial risk of capital loss.

Keywords

Insulin Pump, Diabetes, Medical Device, MODD1, Pivot Pump, FDA Clearance, Going Concern, Nasdaq Delisting, Capital Raise, Biotechnology, Healthcare Technology, Wearable Device